TECH

Bio-Techne Corporation

Healthcare
50.85 +1.08 +2.17% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 7.96B
EV —
Shares Out 156.57M
Revenue (ttm) —
Net Income 165.25M
Beta —
P/E 48.10
Forward P/E —
EPS (ttm) $1.05
P/S —
P/B 3.81
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 6.47%
ROE 8.25%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin —
Debt/Eq 0.14
LT Debt/Eq 8.75%
Quick Ratio —
Current Ratio 4.49
Book/sh 13.34
Cash/sh 1.34
Div Yield 0.63%
Div TTM $0.32
Payout Ratio 30.48%
SMA20 6.31%
SMA50 -2.55%
SMA200 -11.6%
Volume 2,232,905
Avg Volume 2.58M
Rel Volume —
Perf Week -1.61%
Perf Month -10.29%
Perf Quarter -9.02%
Perf Half Y -17.56%
Perf YTD -13.54%
Perf Year 5.26%
Perf 3Y -38.49%
Perf 5Y -52.06%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.0800
TTM Yield 0.63%
TTM Amount $0.32
Payout Ratio 30.48%
3-Yr Growth (CAGR) 0.00%
5-Yr Growth (CAGR) 0.00%

Last 12 Payouts

Period Ex-Date Amount / Share
Q3 2026 ~2026-03-31 $0.0800
Q2 2025 ~2025-12-31 $0.0800
Q1 2025 ~2025-09-30 $0.0800
Q4 2024 ~2025-04-01 $0.0800
Q3 2025 ~2025-03-31 $0.0800
Q2 2024 ~2024-12-31 $0.0800
Q1 2024 ~2024-09-30 $0.0800
Q3 2024 ~2024-03-31 $0.0800
Q2 2023 ~2023-12-31 $0.0800
Q1 2023 ~2023-09-30 $0.0800
Q3 2023 ~2023-03-31 $0.0800
Q2 2022 ~2022-12-31 $0.0800

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company operates in two segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment, representing approximately 72% of net sales, includes the Reagent Solutions division providing specialized proteins such as cytokines, growth factors, antibodies, small molecules, tissue culture sera and cell selection technologies for research and therapeutic development, and the Analytical Solutions division offering manual and automated protein analysis instruments and immunoassays. Key brands include R&D Systems, Tocris Biosciences, Novus Biologicals and ProteinSimple. The Diagnostics and Spatial Biology segment, representing approximately 28% of net revenues, includes the Spatial Biology division providing in-situ hybridization assays and spatial genomic analysis instruments, the Molecular Diagnostics division offering exosome-based liquid biopsy techniques and genetic/oncology kits, and the Diagnostic Reagents division providing calibrators, controls and diagnostic assays for the regulated diagnostics market. The Company serves researchers in academia and industry, pharmaceutical and biotech companies, contract research organizations, diagnostic and therapeutic customers, and clinical laboratories globally through direct sales and distribution partnerships.

Name
Bio-Techne Corporation
Industry
Biotechnology
CEO
Kim Kelderman · President and Chief Executive Officer
Employees
3,800 as of 2025-06-30
IPO Date
2006-10-27
Phone
(612) 379-8854
Address
614 McKinley Place N.E., Minneapolis, MN 55413
Website
http://www.biotechne.com

Key Executives

Name Title FY Pay
Amy E. Herr Director (Board Member) —
John L. Higgins Director (Board Member) —
Robert V. Baumgartner Independent Chair of the Board —
Julie L. Bushman Director (Board Member) —
Kim Kelderman President and Chief Executive Officer —

Latest News